Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo

Switching between raltegravir resistance pathways analyzed by deep sequencing

(2011) Rithun Mukherjee et al.   AIDS

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness

(2010) Zixin Hu et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

(2010) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure

(2009) S. Fransen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors

(2009) A. Low et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

(2009) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance Genotypes

(2009) R. Quercia et al.   JOURNAL OF VIROLOGY

Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses

(2009) Marc Witmer et al.   METHODS

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

(2009) O. Delelis et al.   NUCLEIC ACIDS RESEARCH

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy*

(2008) C Charpentier et al.   HIV MEDICINE

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

(2008) Vincenzo Summa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE